Missy Broome

It's Missy!

Clay Siegall – A Cancer Fighting Giant

Seattle Genetics, Inc. was founded in 1998 and is Washington state’s top biotech company that is the forerunner in creating ADC (antibody-drug conjugate) drugs. The drugs are designed to target antigens that delivers a toxin into cells that causes Hodgkin lymphoma, myeloid leukemia, bladder cancer, urothelial cancers, breast cancer, and other types of cancer cells. The toxins are designed to kill the cancer cells but does not harm surrounding normal tissues, unlike chemo.

The future goal of Seattle Genetics is to ennoble itself from a biotech firm to a national and international pharmaceutical company. Seattle Genetics has 11 drugs containing the cancer killing toxins, four of which are approved by the Food and Drug Administration and are designed for immediate sales in the U.S. and international markets. Seattle Genetics is using its own research skills in oncology to manage all of the rights to new drugs and bring them to world-wide pharma markets.

At the head of these innovative drug concepts is Clay Siegall, a tenacious and avant-guard entrepreneur. He serves as the firms’ Co-founder, CEO, Chairman, and President, of Seattle Genetics. He attended and graduated from the University of Maryland with a B.S. in Zoology and a Ph.D. in Genetics from George Washington University. Mr. Siegall has 20 years of experience in researching cancer and varied therapeutic drug advancements, having worked at major research institutes, including Bristol-Myers Squibb from 1991 to 1995. Clay Siegall desires to elevate Seattle Genetics ability to solely market its new drugs internationally. This effort has begun by Siegall opening an office in Switzerland.

Mr. Siegall has been busy serving scientific boards of many cancer-related foundations and serves as a Director on the Washington Biotechnology and Biomedical Association and the Fred Hutchinsoon Cancer Research Business Alliance. Over the years, he had authored many scientific papers and serves on editorial boards for science journals. He has pending patents and has receive notable awards for his toxin research.

Leave a Reply